Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

June 25th 2024

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

Patient with Newly Diagnosed CLL with High-Risk Features

June 25th 2024

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL

June 24th 2024

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

June 18th 2024

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Patients With CLL Place the Most Value on Treatments That Prolong PFS

June 18th 2024

A survey of adult patients with chronic lymphocytic leukemia demonstrated that respondents preferred therapies that increased PFS vs other attributes.

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

June 17th 2024

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

June 17th 2024

Acalabrutinib and zanubrutinib monotherapy displayed better real-world safety and efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma compared with ibrutinib.

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL

June 17th 2024

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis

June 16th 2024

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

CD19-Directed CAR T-Cell Therapy Demonstrates Clinical Efficacy in Richter Transformation

June 16th 2024

Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.

Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL

June 15th 2024

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Earlier Use of Acalabrutinib Associated With Improved Survival in CLL

June 14th 2024

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL

June 14th 2024

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Extends PFS in First-Line CLL

June 13th 2024

Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs chemoimmunotherapy and vs venetoclax plus rituximab in frontline CLL.

Dr Porter on Community-Based CAR T-Cell Therapy Administration for R/R CLL

June 12th 2024

David L. Porter, MD, discusses the utility of CAR T-cell therapy in the community setting for relapsed/refractory chronic lymphocytic leukemia.

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

June 11th 2024

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

Dr Shadman on the Comparative Efficacy of Currently Available BTK Inhibitors in CLL

June 6th 2024

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

May 30th 2024

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

Dr Porter on the Future of CAR T-Cell Therapy in Relapsed/Refractory CLL

May 30th 2024

David L. Porter, MD, discusses the future of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

May 28th 2024

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.